FDA
Hazards Ahead for FDA’s Drug Review Process
In June 2025 the U.S. Food and Drug Administration (FDA) launched the Commissioner’s National Priority Voucher Program (CNPV), billing the initiative as “accelerated drug review for companies supporting U.S. national interests.”
Hazards Ahead for FDA’s Drug Review Process
